Navigation Links
Aware, Inc. Reports Second Quarter 2014 Financial Results
Date:7/22/2014

an">10,6926,661Operating income before patent related income1,3825432,6922,744Income from patent arrangement---780Operating income after patent related income1,3825432,6923,524Other expense(59)-(59)-Interest income5278139160Income from continuing operations before income taxes1,3756212,7723,684Provision for income taxes5101561,0261,247Income from continuing operations8654651,7462,437Loss from discontinued operations, net of income taxes-(158)-(273)Net income$865$307$1,746$2,164Basic net income per share:Basic net income per share from continuing operations$0.04$0.02'/>"/>
SOURCE Aware, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology news :

1. Aware, Inc. Reports First Quarter 2012 Financial Results
2. Aware, Inc. Reports Second Quarter 2012 Financial Results
3. Aware, Inc. Reports Third Quarter 2012 Financial Results
4. Aware, Inc. Declares Special Cash Dividend of $1.80 Per Share, or Approximately $40 Million in Total
5. NASDAQ Sets Ex-Dividend Date for Aware, Inc.s Special Cash Dividend of $1.80 Per Share
6. Aware, Inc. Reports First Quarter 2013 Financial Results
7. Aware, Inc. Reports Second Quarter 2013 Financial Results
8. Aware, Inc. Reports Third Quarter 2013 Financial Results
9. Patient in vegetative state not just aware, but paying attention
10. NASDAQ Sets Ex-Dividend Date for Aware, Inc.s Special Cash Dividend of $1.75 Per Share
11. Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... La 10 th International Conference on Genomics ... 22 al 25 de octubre de 2015 en ... conferencia celebra su décimo aniversario. Desde su inauguración en el ... reuniones anuales más influyentes del mundo en el campo ,ómico, ... y mejores a nivel científico. ICG-10 se ...
(Date:7/31/2015)... -- The 10 th International Conference on Genomics (ICG-10, ... 2015, in Shenzhen , China ... th anniversary this year. Since its inauguration in 2006, ... meetings in the ,omics, fields, and is one of the ... ICG-10 focuses on recent breakthroughs and advances in ,omics, research ...
(Date:7/27/2015)... LOS ANGELES , July 27, 2015 /PRNewswire/ ... providing evidence- and experience-based clinical improvement solutions, today ... coordination solution is now available on Android smartphones ... at inpatient and post-care organizations can use ZynxCarebook ... the same patient,s condition, streamline care transitions to ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... with more corals and fish generate predictably greater levels ... This has important implications for understanding the behaviour of ... monitoring environmental health by listening to reefs. Contrary ... noisy places, with fish and invertebrates producing clicks and ...
... their abilities to counsel patients on a healthy diet and ... to a study by the University of Michigan Cardiovascular Center. ... time, being overweight, and if the doctor had adequate training ... study, published online ahead of print Oct. 1 in ...
... (September 21, 2010) For decades scientists believed ... contact with Homo sapiens , but new ... shows these sturdy ancients could adapt, innovate and ... by anthropologist Julien Riel-Salvatore challenge a half-century of ...
Cached Biology News:Taking the pulse of coral reefs 2Doctor's health habits affect patient counseling 2Neanderthals more advanced than previously thought 2
(Date:7/30/2015)... , July 30, 2015 Ascendis Pharma ... that applies its innovative TransCon technology to address ... results from a six-month Phase 2 study to ... Growth Hormone in 53 treatment-naïve, pre-pubertal children with ... are extremely pleased with the top-line results from ...
(Date:7/30/2015)... 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... the second $1.0M tranche under a previously awarded ... valued at up to $3.0 million to support ... as a potential medical countermeasure to mitigate acute ... awarded an initial $1.0 million under this grant ...
(Date:7/30/2015)... ... 30, 2015 , ... GEA's Pony™ NS2006L is ... up to 1500 bar. The sanitary design gauge of the NS2006L is well ... The Pony™ NS2006L homogenizer is an ideal solution for the processing of ...
(Date:7/29/2015)... , July 30, 2015 ... santé, publie ses résultats pour le premier semestre ... commente les résultats. Visionner l,interview vidéo ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de l,interview ... - Moteurs de croissance - Diabète ...
Breaking Biology Technology:Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... (Nasdaq: NXXI ), a developer and marketer ... levels, improve cardiovascular health, enhance memory and address chronic ... it redeemed all of its Series I outstanding Convertible ... shares. The Company redeemed 3,594 shares for a total ...
... 5:00 p.m. EDT - SOUTH SAN FRANCISCO, Calif., ... SNSS ) today reported financial results for the fourth ... for the year ended December 31, 2008 was $5.4 ... of December 31, 2008, cash, cash equivalents and marketable ...
... on probiotic microorganismsActive ingredient easily integrated into consumer products ... Association of Dental Research annual conference in Miami ... Germany and MIAMI, April 1 With an eye ... affecting an estimated 5 billion people world-wide, BASF -- ...
Cached Biology Technology:Nutrition 21 Redeems Series I Convertible Preferred Shares 2Nutrition 21 Redeems Series I Convertible Preferred Shares 3Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 2Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 3Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 4Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 5Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 6Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 7Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 8Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 9Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 10Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results 11BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 2BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 3BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 4BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth 5
... The Biomek FX P is ... an,up-to-date hardware design for greater positional accuracy and ... just about any application. It can be configured ... its large deck capacity, the Biomek FX P ...
BD Falcon, microtest ELISA plate 96 well flat-bottom, clear. Polystyrene, nonsterile, no lid (25/sp, 100/ca) Packaging: 25 / pack, 100 / case ...
... GenomeLab GeXP Genetic Analysis System provides high-throughput, ... PCR*. The systems patented priming strategy ... PCR analysis to just a few genes ... more genes per reaction and more samples ...
... electrophoresis hood is a component ... Placed on the transilluminator, it ... and provides a darkroom environment ... lab bench. This 13 x ...
Biology Products: